Search Results

Protara Therapeutics, Inc. (Nasdaq: TARA) today announced positive data from three-month evaluable carcinoma in situ (CIS) patients treated across its ongoing clinical program of TARA-002, the Company’s investigational cell-based therapy, in high-risk Non-Muscle Invasive Bladder Cancer (NMIBC), including Bacillus Calmette-Guérin (BCG)-Unresponsive, BCG-Experienced and BCG-Naïve patient populations.

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced additional encouraging data from the Phase 1a dose-escalation component of its ongoing ADVANCED-1 clinical trial of TARA-002.

TARA Biosystems Partners with Scipher Medicine ®

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, announced the execution of a territory exclusive distribution agreement in Hong Kong and Macau.

Protara Therapeutics, Inc. today announced that dosing is now underway in the Phase 2 STARBORN-1 trial evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of pediatric patients with lymphatic malformations (LMs).